Stay updated on GB5121 in Refractory CNS Lymphoma Clinical Trial
Sign up to get notified when there's something new on the GB5121 in Refractory CNS Lymphoma Clinical Trial page.

Latest updates to the GB5121 in Refractory CNS Lymphoma Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedA 403 Forbidden error page is now shown, replacing the study record content and indicating that access to the page is blocked.SummaryDifference17%

- Check36 days agoChange DetectedRevision: v3.6.6 is now displayed, replacing the previous Revision: v3.6.5. This reflects a minor update to the page's revision label rather than any content change to the study details.SummaryDifference0.1%

- Check58 days agoChange DetectedThe page footer revision was updated from v3.6.4 to v3.6.5, indicating a new release of the page. This update reflects version control rather than substantive changes to the study details.SummaryDifference0.1%

- Check72 days agoChange DetectedThe sponsor entity name was updated to Gossamer Bio USA, Inc. (GB005, Inc.), and the page revision progressed from v3.6.3 to v3.6.4.SummaryDifference0.2%

- Check93 days agoChange DetectedThe page now displays Revision: v3.6.3 in place of Revision: v3.6.2, indicating an update to the interface version. This is a UI/versioning change and does not alter the study data or its presentation beyond the version label.SummaryDifference0.1%

- Check100 days agoChange DetectedThe page now shows a new revision tag indicating v3.6.2, updating the page's version label. This reflects an internal update to the page template rather than changes to study data or content.SummaryDifference0.1%

Stay in the know with updates to GB5121 in Refractory CNS Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the GB5121 in Refractory CNS Lymphoma Clinical Trial page.